Abstract 3392
Background
The French health authorities are not in favor of systematic lung cancer (LC) screening and instead advocate boosting measures aimed at prohibiting smoking and controlling the use of tobacco. In this context, it appeared important to have a clear insight into the characteristics of individuals who have already undergone a screening test for LC.
Methods
The French nationwide observational survey, EDIFICE 6, was conducted online from 26 June-28 to July 2017 on a core sample of 12 046 individuals (age, 18-69 years). Representativeness was ensured by quota sampling on age, gender, profession, and stratification by geographical area and type of urban district. Multivariate stepwise logistic regression analysis was conducted to identify the characteristics of individuals likely to undergo LC screening. The present analysis included 3114 individuals (age, 55-69 years) with no history of cancer.
Results
Fifteen percent of the study population declared having already undergone a screening test for LC. Compared to individuals who had never been screened for LC, these 15% were characterized by a higher proportion of men (64% vs 54%, P<0.05), of retired individuals (59% vs 54%, P<0.05), and of current and former smokers (34% vs 21%, P<0.05, and 47% vs 38%, P<0.05, respectively). Mean age and social vulnerability did not differ significantly between the screened/unscreened populations. In multivariate analysis, items associated with undergoing screening included current smoking (OR=1.92, 95% CI=1.54-2.38), low body mass index (OR=1.92, 95% CI=0.97-3.57), male gender (OR=1.61, 95% CI=1.31-1.99), and higher education (OR=1.29, 95% CI=1.06-1.58). In contrast, belonging to the socioprofessional category of unskilled workers was associated with the likelihood of non-uptake of a LC screening exam (OR=0.38, 95% CI=0.16 – 0.78).
Conclusions
Individuals with a history of smoking or who currently smoke are the most likely to undergo screening for LC. The social criteria most frequently related to either uptake of or resistance to LC screening were higher education and belonging to lower socioprofessional categories, respectively.
Clinical trial identification
Editorial Acknowledgement
edical writing assistance was provided by Isabelle Lawrence, Potentiel d’Action (France)
Resources from the same session
2018 - Genomic landscape and its correlation with TMB, CD8 TILs and PD-L1 expression in Chinese lung squamous cell carcinoma
Presenter: Caicun Zhou
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3833 - Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma
Presenter: Zhijie Wang
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
4319 - Cardiac events in stage III non-small cell lung cancer (NSCLC) treated in daily clinical practice: is it time for cardiovascular screening and follow-up?
Presenter: Juliette Degens
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3466 - Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: incidence and outcome
Presenter: Susana Cedres Perez
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2909 - Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study
Presenter: Igor Bondarenko
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3815 - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy
Presenter: Konstantin Dragnev
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5061 - Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small-cell lung cancer. A multicenter phase II trial (SAKK 15/12)
Presenter: Hansjörg Vees
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5172 - Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study
Presenter: Janna Schoenmaekers
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1348PD, 1349PD and 1350PD_PR
Presenter: Wilfried Eberhardt
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1364PD and 1806PD
Presenter: Pieter Postmus
Session: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast